Regulations and Regulatory Advocacy
The U.S. District Court for the District of Connecticut this week largely dismissed a lawsuit alleging that Yale New Haven Hospital violated its fiduciary duties by selecting a retirement plan with excessive fees or poorly performing investments. The court allowed certain ancillary claims related…
In comments submitted today, AHA encouraged the Department of Health and Human Services to finalize as written its proposed rule regarding statutory conscience protections.
January 31, 2023
April Tabor
Secretary Federal Trade Commission
600 Pennsylvania Avenue NW
Suite CC-5610 (Annex C)
Washington, DC 20580
Re: Notice of Proposed Rulemaking, Federal Trade Commission; Non-Compete Clause Rule; 88 Fed. Reg. 3482 (RIN: 3084-AB74) (January 19, 2023)
Dear Ms. Tabor:
The AHA shares CMS’ goals to improve patient access to provider information and to facilitate health information exchange and data reporting. However, we are concerned that adding one more provider directory requirement will not support patients in accessing the information they need about their…
On Oct. 31, the Centers for Medicare & Medicaid Services (CMS) issued its calendar year (CY) 2023 final rule for the home health (HH) prospective payment system (PPS).
A new memorandum from the Centers for Medicare & Medicaid Services is reinforcing the agency’s role in enforcing regulatory expectations that patients and hospital staff have an environment that prioritizes their safety to ensure effective delivery of health care.
The AHA letter to the Centers for Medicare & Medicaid Services, cautioning against softening standards designed to maintain the safety and quality of laboratory testing in the U.S., including those regulating the professionals who staff the nation’s Clinical Laboratory Improvement Amendments-…
The Centers for Disease Control and Prevention yesterday updated its guidance to help clinicians evaluate and test patients with relevant history, signs and symptoms for monkeypox
AHA Friday urged lawmakers to consider certain changes to the Verifying Accurate Leading-Edge IVCT Development (VALID) Act.
AHA provides feedback on the Food and Drug Administration
Safety and Landmark Advancements (FDASLA) Act (S.4348).